Oropharynx Cancer, Recurrent clinical trials at University of California Health
1 research study open to eligible people
open to eligible people ages 18 years and up
The purpose of this study is to compare any good or bad effects of using pembrolizumab (an experimental drug) and radiation therapy (RT), compared to using cisplatin chemotherapy and radiation therapy (RT) in the treatment of patients with head and neck squamous cell carcinoma (HNSCC).
Our lead scientists for Oropharynx Cancer, Recurrent research studies include Loren Mell, MD.